An independent ERC was commissioned to perform a systematic review of key clinical questions, the results of which were considered by the GWC for incorporation into this guideline
Beta-1 selective blockers (except atenolol) or verapamil should be considered for prevention of SVT in patients without Wolff-Parkinson-White (WPW) syndrome (Class IIa)
For these and all recommended drug treatment regimens, the reader should confirm dosage with product insert material and evaluate for contraindications and interactions
D
Associated with a small risk of sudden cardiac death
Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation
The use of amiodarone can lead to Ventricular Fibrillation (VF) in some of these patients
The loading dosage of 150 mg appeared to be preferred, and the maintenance period was better to less than 12 hours
†A loading dose of 600 mg per day is usually given for one month or 1000 mg per day over 1 week
Amiodarone and digoxin are no longer mentioned in the new guidelines for the acute management of
Pearls & Pitfalls Their efficacy in reducing the risk of accelerated conduction of AF in WPW patients is unclear
The use of amiodarone for pre-excited atrial fibrillation (AF) with Wolff-Parkinson-White (WPW) syndrome has been reported to lead to spontaneous
AF with an accessory pathway (Wolff Parkinson White) Amiodarone is reasonably effective if dosed appropriately (more on the dose below )
Intravenous amiodarone might be an alternative for acute treatment of AF and WPW syndrome in patients characterized by stable hemodynamics, relatively low
In addition, the administration of intravenous amiodarone in AF with WPW syndrome is potentially harmful
Amiodarone is commonly utilized for treating both supraventricular and ventricular arrhythmias
0%) restored to sinus rhythm by amiodarone with the conversion time of 486
Six patients with Wolff-Parkinson-White (WPW) syndrome were given long-term treatment with amiodarone
Prior
5–39
P waves vary
0 gm of amiodarone, results in prolongation of refractoriness of the atrium, the AV node, the His-Purkinje system, the ventricle, and the
Dose (Etomidate): Start with 0
In addition to the superior efficacy compared with most other antiarrhythmic drugs, amiodarone has very little negative inotropic activity and a low rate of ventricular proarrhythmia, making it advantageous for Catheter ablation of the accessory pathway should be performed if high-risk features are found on EP testing
darone dose results in depression of A–V node conduction with little direct effect on atrial or ventricular properties
First described in 1930 by Louis Wolff, John Parkinson and Paul Dudley White
Amiodarone is only used after defibrillation (or cardioversion) and epinephrine (first line medication) fail to convert VT/VF
These effects tend to be dose dependent
If necessary, direct antiarrhythmic therapy, including antiarrhythmic The metoprolol dose of 200 μg/mL was based on a 20% HR reduction standard for heart beta-blockade according to data described previously (3,18)
The loading dosage of 150 mg appeared to be preferred, and the maintenance period was better to
The efficacy of amiodarone was evaluated in 85 patients with supraventricular tachycardia (SVT) re-fractory to several antiarrhythmic agents (mean 3
Response to amiodarone treatment was con-sidered excellent (no recurrence of SVT Amiodarone hydrochloride tablets can cause nerve problems